NovoCure (NVCR) Convertible Debt (2023 - 2024)
NovoCure's (NVCR) quarterly Convertible Debt came in at $556.5 million in Q2 2024, down 2.16% quarter-over-quarter from $568.8 million in Q4 2023.
NovoCure (NVCR) Convertible Debt (2023 - 2024) Analysis & Trends
NovoCure has disclosed Convertible Debt across 2 years of filings, most recently posting $556.5 million for Q2 2024.
- Convertible Debt for Q2 2024 came in at $556.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $556.5 million (changed N/A YoY), and the FY2023 annual result was $568.8 million, changed N/A from the prior year.
- Convertible Debt came in at $556.5 million for Q2 2024 at NovoCure, down from $568.8 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $568.8 million in Q4 2023 to a low of $556.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | NovoCure | 1.63 Bn | 1.20 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 556.51 Mn |
| Dec 31, 2023 | 568.82 Mn |